1 active not recruiting, 1 recruiting, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive: new trials by email Literature Review of Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive trials Research Report on Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Adavosertib, Belinostat, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 1 | Terminated | National Cancer Institute (NCI) | 20 | 2015-08-18 | 2026-01-30 |
Blast Crisis (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelomonocytic, Chronic (1) · Leukemia, Myelomonocytic, Juvenile (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm, Residual (1)
Bone Marrow Diseases (3) · Carcinogenesis (3) · Cell Transformation, Neoplastic (3) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Leukemia, Myeloid (3) · Myeloproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Immune System Diseases (2)
Biopsy (1) · Blood Component Removal (1) · Cyclophosphamide (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · adavosertib (1) · belinostat (1) · fludarabine (1)
Fred Hutchinson Cancer Center (1) · National Cancer Institute (NCI) (1) · Ohio State University Comprehensive Cancer Center (1)
United States (3)
Danielle A Shafer (1) · Elizabeth Krakow (1) · Sumithira Vasu, MD (1)
N01CM00100 (1), UM1CA186644 (1), UM1CA186716 (1)